Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination

Hahn, Ulrike; Alex, Michaela; Czerny, Claus-Peter; Böhm, Reinhard; Beyer, Wolfgang

doi:10.1016/j.ijmm.2003.12.002

Cited by 35 publications

(42 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Escherichia coli BL21-CodonPlus-RIL cells (Stratagen, LaJolla, USA) harbouring the plasmid pREP4 (Qiagen, Venlo, Netherlands) and pQE-30 (Qiagen, Venlo, Netherlands) encoding either rPA83 or rBclA were grown and purified as previously described (Hahn et al 2004) for the proteins used in the ELISA. The FIS suspension from the SLSV strain (34F2) was prepared as previously described (Brossier et al, 2002, 661-664) with some modifications.…”

Section: Serologymentioning

confidence: 99%

Comparative analysis of the immunologic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in a ruminant model

Ndumnego

Köhler

Crafford

et al. 2016

Veterinary Immunology and Immunopathology

Self Cite

View full text Add to dashboard Cite

Highlights Anti-BclA IgG absent in goats immunized with the Sterne 34F2 live spore vaccine  Booster vaccinations with Sterne vaccine induced robust humoral immunity in goats  Preliminary challenge studies indicate infective dose of 36 spores in naive goats  Anthrax infection was peracute in naïve goats with incubation period of 2-3days  Four in five goats protected against anthrax a year after single Sterne vaccination AbstractThe Sterne 34F2 live spore vaccine (SLSV) developed in 1937 is the most widely used veterinary vaccine against anthrax. However, literature on the immunogenicity of this vaccine in a target ruminant host is scarce. In this study, we evaluated the humoral response to the booster vaccination following the first immunization is suggested in order to achieve a robust immunity. Results from this study indicate that this crucial second vaccination can be administered as early as 3 months after the initial vaccination.

show abstract

Section: Serologymentioning

confidence: 99%

Comparative analysis of the immunologic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in a ruminant model

Ndumnego

Köhler

Crafford

et al. 2016

Veterinary Immunology and Immunopathology

Self Cite

View full text Add to dashboard Cite

show abstract

“…We have shown that mice immunised with lysine based dendrons C 0 and C 18 (Fig. 1) produce antibodies to encapsulated PA-DNA [12].…”

Section: Introductionmentioning

confidence: 90%

A Study of PA DNA/Dendron Nanoparticles for Genetic Immunisation Against Anthrax

Ribeiro¹,

Rijpkema²,

Durrani³

et al. 2008

TOVACJ

View full text Add to dashboard Cite

Protective antigen (PA), the binding subunit of toxins produced by Bacillus anthracis is singularly the most important antigen required for specific immunity to anthrax disease. We used cationic poly-lysine dendrons to develop a genetic anthrax vaccine. Plasmid CMV/ER PA83 which encoded full length PA 83 was complexed with dendrons to form dendriplexes. Two types of dendron were used: C 0 and C 18 .These were mixed with DNA to form dendriplexes, of approximately 80 nm in size, which were tested for immunogenicity. A/J and BALB/c mice were vaccinated with dendriplexes containing 1 g and 50 g plasmid DNA per dose over a period of 6 weeks. Immunisation with naked PA DNA did not induce an antibody response even after secondary boosting, whereas both dendriplexes produced strong anti-PA antibody response. This response was dose dependent. We conclude that dendriplexes show superior immunogenicity compared to naked PA DNA in both mouse strains and that C 18 dendriplexes with 50 g plasmid DNA are most efficacious. However, the elicited antibodies did not neutralise lethal toxin in vitro. Therefore further work is required to improve these preparations in order to elicit functional antibodies.

show abstract

“…However, a replicon construct designed to express the 63-kDa form of PA failed to protect immunized mice against challenge with spores from the Sterne strain, whereas a similar construct designed to express PA83 was protective [26]. Immunization of mice with DNA constructs designed to express either secreted or cellular PA63 (or PA83) conferred protection against challenge with anthrax toxin [27,28]. Galloway et al showed that immunization with a PA63 construct followed by a boost with rPA83 afforded protection in a rabbit challenge model with spores of the Ames strain, but only one rabbit with this immunization regime was evaluated [29].…”

Section: Introductionmentioning

confidence: 99%

A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection

Hepler

Kelly

McNeely

et al. 2006

Vaccine

View full text Add to dashboard Cite

Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination

Cited by 35 publications

References 24 publications

Comparative analysis of the immunologic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in a ruminant model

Comparative analysis of the immunologic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in a ruminant model

A Study of PA DNA/Dendron Nanoparticles for Genetic Immunisation Against Anthrax

A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection

Contact Info

Product

Resources

About